UMC Health System Partners with Omnicell for Advanced Services Solutions to Streamline Medication Management & Enhance Clinical Outcomes

Omnicell | February 15, 2022

Omnicell, Inc., a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that UMC Health System (“UMC”) in Lubbock, Texas, has selected Omnicell’s comprehensive portfolio of Advanced Services solutions to support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies.

UMC has signed a 10-year sole source agreement for Omnicell’s cloud-based portfolio of solutions, including central pharmacy automation and point of care dispensing systems. The partnership is also expected to support UMC’s goals of expanding community pharmacy services through opportunities with Omnicell’s 340B services and EnlivenHealth’s patient engagement solutions, helping UMC to drive operational efficiency across its continuum of care. More importantly, these solutions will empower pharmacy staff and clinicians to focus on higher value tasks that support patient safety.

As a public hospital with a 40-year tenure supporting the Lubbock community, UMC has experienced an increase in demand for its services. According to U.S. Census data, Texas has one of the highest uninsured population rates – at 18.4 percent in 2019, nearly double the national average. Programs like the federal 340B Drug Pricing Program and technology-enabled patient engagement solutions are intended to help improve health outcomes for these underserved communities.

“At UMC, our top priority is patient safety and ensuring healthy outcomes for our community. Partnering with Omnicell, we are building an advanced pharmacy technology strategy that aligns with our vision to streamline and advance the pharmacy and nursing practice across our system. Most importantly, we are laying a technology foundation that will enable the best patient care.”

John Lowe, vice president of Support Services at UMC Health System

UMC has embraced the industry-defined vision of the Autonomous Pharmacy, a roadmap designed to develop a zero-error, fully automated medication management infrastructure. Through automation, intelligence, and expert services, the Autonomous Pharmacy is expected to drive performance and outcomes, and empower clinicians to shift their focus from manual administrative functions to patient support needs.

“As medication management becomes more complex, we believe health systems need end-to-end, cloud-based solutions that will allow them to work smarter, while supporting safe, efficient pharmacy care,” said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. “We’re confident that Omnicell’s partnership with UMC will provide comprehensive solutions that bridge acute and ambulatory care to help enhance performance and that are designed to deliver the highest levels of patient safety across the health system.”

About UMC

UMC Health System is a national award-winning health system comprised of over 4,600 team members and more than 30 care locations. We are proud to partner with Texas Tech University Health Sciences Center to provide the best care to West Texas and Eastern New Mexico. Whether you are managing a chronic condition, dealing with an unexpected illness, or simply working to stay healthy, we are passionate about getting you well and helping you stay that way. At UMC, Our Passion is You.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. 


Why partner with patients? to improve the quality of healthcare. to inform and educate patients and the public. to build confidence with the public. to make better use of health care resources. to improve how health services are evaluated.


Why partner with patients? to improve the quality of healthcare. to inform and educate patients and the public. to build confidence with the public. to make better use of health care resources. to improve how health services are evaluated.

Related News



SWORD Health | July 05, 2022

Sword Health, the fastest growing digital musculoskeletal (MSK) solution on the market, announced that it is launching a new brand that reflects its mission to free 2 billion people from pain. This change comes at an immense time of progress for the company as it sets its sights on growth in 2023. The new brand position is communicated through a redesigned institutional as well as a modernized logomark composed of two circular shapes representing the company’s focus on every member’s unique journey to a healthier life – the outlined circle represents prevention, and the filled circle treatment. The company will also be softening the look and feel of its digital applications, including the digital therapist and member app. Additionally, its color palette, iconography, photography, member experience, and apparel have all undergone a strategic upgrade to reflect the evolution of Sword Health. "We are announcing the beginning of a global movement to free the world from pain. It's more than just a new look and feel to us, it's the culmination of years of research and development, aimed at supporting the core goal of healing people’s pain. We're confident this movement expresses both the transformation of our company as a whole and the future of a pain-free world." Virgilio Bento, Founder and CEO of SWORD Health Sword Health believes in the power of people to recover at home, without resorting to surgeries or opioids. Since launching in 2015, Sword Health has worked with insurers, health systems and employers worldwide to make high quality physical care accessible to everyone. Sword Health is setting a new standard for clinical outcomes: the company’s results are of a higher quality than the traditional model, and it is delivering real cost savings to their customers while helping their employees heal quickly and safely. About Sword Health Sword Health is the world’s fastest growing digital musculoskeletal (MSK) care provider, on a mission to free 2 billion people from acute, chronic, and post-surgical pain. It is the first digital solution to pair its members with a licensed physical therapist and the Sword Health Digital Therapist, to deliver a clinically-proven, personalized treatment plan that is more effective, easier, and less expensive than the traditional gold standard of care. Sword Health believes in the power of people to recover at home, without resorting to imaging, surgeries or opioids. With the preventative care delivered through Sword+, it is the industry's only end-to-end digital MSK solution. Since launching in 2015, Sword Health has worked with insurers, health systems, and employers in the U.S., Canada, Europe, and Australia to make high quality musculoskeletal care accessible to everyone.

Read More


Matrix Medical Network Announces Sale of Decentralized Clinical Trials Service Line to Emvenio Research

Matrix Medical Network | August 09, 2022

Matrix Medical Network® and Emvenio Research® announced the sale of the Matrix Clinical Trials service line to Emvenio, a leading decentralized clinical trials company. The transaction will provide Emvenio with proven DCT capabilities, while allowing Matrix to focus on improving the health and wellness of health plan members, and keeping America's workers productive and safe, through its design of custom and flexible clinical solutions. Post transaction, Emvenio will deploy additional resources, technology, and capital to continue to grow and scale its clinical trials services both domestically and internationally, making clinical research more accessible, equitable, and effective. "At the onset of the pandemic Matrix mobilized quickly to provide decentralized clinical trial solutions in support of vaccine and therapy development for COVID-19. We leveraged our skilled clinicians, Mobile Health Clinics, and experienced leaders to adapt traditional clinical trials protocols to better reach and recruit diverse, underserved, and high-risk patients. We are incredibly proud of the remarkable work the Matrix Clinical Trials team started during the pandemic and continued to expand upon. I am excited about this transition and look forward to watching the leaders and employees of Emvenio continue to develop and deliver decentralized clinical trial solutions that best serve those patients who most need access to new treatments." Catherine J. Tabaka, Matrix Chief Executive Officer "The leaders of Matrix Clinical Trials showed leadership, agility, creativity, and perseverance in building a decentralized clinical trial organization from the ground up," said Keith Henthorne, Emvenio Chief Executive Officer. "I look forward to working closely with these leaders in order to build upon this solid foundation established by Matrix and to continue making clinical trials more accessible to diverse populations throughout the world. To ensure continued access to clinical trials for the patients who need it most, many Matrix employees and leaders will be a part of the Emvenio team going forward. I am proud to be working alongside strong leaders like Dr. Daniel Castillo and Thad Wolfram, amongst others, and look forward to growing the company with them." About Matrix Medical Network Matrix Medical Network has provided expert care and health services to millions of at-risk individuals where they live and work for more than 20 years. The organization's network of approximately 4,000 clinicians meets individuals wherever they are, to assess their health and safety, identify and close care gaps, and offer life-changing services that activate them to manage their own health. About Emvenio Emvenio is a leading decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Its mission is to eliminate the barriers to clinical trials by engaging with people in their communities and in their homes. Emvenio's technology enabled, innovative network of Mobile Research Sites, At Home Visits, and Virtual Visits are a unique blend of global DCT capabilities that can be deployed to better reach, recruit and retain diverse patient populations, while improving the clinical trial experience. These capabilities offer global DCT participant-centric approaches that provide flexibility, meet the most challenging clinical trial demands, and provide convenience for patients and caregivers in a compliant manner. Emvenio is transforming how all stakeholders engage in, experience, and deliver clinical research.

Read More


Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

Conformis, Inc. | August 02, 2022

Conformis, Inc. a leading medical device company that features personalized knee and hip replacement products, announced it has entered into a multi-year agreement with Vizient, Inc., the nation's largest member-driven health care performance improvement company. “We are excited to offer personalized orthopedic implants to Vizient’s large membership of healthcare facilities through this contract. As more orthopedic patients and surgeons seek personalized solutions, increased awareness and ease of access to our product portfolio is more important than ever. The Vizient agreement connects us to a significant number of providers, many of which have limited access and awareness of our products and our new Platinum Services Program,” Mark Augusti, Chief Executive Officer and President of Conformis The agreement gives increased access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, and includes Identity Imprint™, a personalized knee replacement system; Image-to-Implant® Platinum Services Program, a patient-elected deluxe upgrade option to obtain a fully personalized knee replacement implant; and, Cordera™ Match Hip System, a personalized primary hip replacement solution. Conformis implants improve efficiency and reduce overall costs for medical facilities. Researchers at the University of Washington in Seattle found that fully personalized total knee arthroplasty is cost-effective in comparison to a standard, off-the-shelf implant. Ongoing research suggests that fully personalized implants further reduce total costs to the healthcare system because patients recover more quickly and are less likely to require follow-up corrective surgeries. About Conformis, Inc. Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

Read More